m**c
发帖数: 7349 | 1 Yet perhaps the most intractable problem remains sparking investments to
expand the arsenal against these microbes.
“The basic issue is this research is needed but we don’t have the
business models to facilitate or encourage this,” Fukuda says. Drugmakers
often say that without a different incentive structure—perhaps government
rewards for new classes of antibiotics—it does not make good business sense
to invest in antibiotics when they could focus on projects that would
command higher profits, such as new drugs to fight cancer.
In Spellberg’s emergency room, however, patients simply cannot afford to
wait. |
|
